Pulmonx (LUNG) Stock Price, News & Analysis

Company Overview

Pulmonx Corporation is a medical device company focused on developing and commercializing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its technologies are designed to improve lung function and quality of life by reducing the impact of damaged, overinflated portions of the lungs.

The company’s primary product is the Zephyr Endobronchial Valve, a small, one-way valve placed in the airways during a bronchoscopic procedure. The valve is intended to block airflow into diseased areas of the lung while allowing trapped air and fluids to escape, helping healthier portions of the lung function more effectively. Pulmonx also offers the Chartis Pulmonary Assessment System, which helps physicians evaluate airway anatomy and collateral ventilation to identify patients who may be appropriate candidates for Zephyr Valve treatment.

Pulmonx markets its products through direct sales and distribution channels in the United States and international markets. The Zephyr Valve has received regulatory authorization in the United States and is available in various other geographies, including Europe. The company’s business is centered on expanding awareness and adoption of bronchoscopic lung volume reduction as a less invasive alternative for appropriately selected patients with severe emphysema.

Key Stats

• Today's Range: $1.74 to $1.93
• 50-Day Range: $1.78 to $2.50
• 52-Week Range: $1.13 to $2.89
• Volume: 428,688 shs
• Average Volume: 480,496 shs
• Market Capitalization: $77.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.67
• Consensus Rating: Moderate Buy

Pulmonx Stock Analysis - MarketRank™

Pulmonx scored higher than 66% of companies evaluated by MarketBeat, and ranked 287th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Pulmonx has a consensus price target of $7.67, representing about 325.9% upside from its current price of $1.80.

Amount of Analyst Coverage

Pulmonx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pulmonx are expected to grow in the coming year, from ($1.05) to ($0.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pulmonx is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pulmonx is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pulmonx has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.02% of the float of Pulmonx has been sold short.

Short Interest Ratio / Days to Cover

Pulmonx has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pulmonx has recently decreased by 5.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulmonx does not currently pay a dividend.

Dividend Growth

Pulmonx does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Pulmonx has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Pulmonx this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $177,048.00 in company stock.

Percentage Held by Insiders

7.50% of the stock of Pulmonx is held by insiders.

Percentage Held by Institutions

91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:LUNG
• CIK: 1127537
• Web: pulmonx.com
• Phone: 1-650-364-0400
• Fax: N/A
• Employees: 296
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Pulmonx: $7.67
• High Price Target: $14.00
• Low Price Target: $4.00
• Potential Upside/Downside: +325.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$54 million
• Net Margins: -55.03%
• Pretax Margin: -54.35%
• Return on Equity: -96.66%
• Return on Assets: -38.32%

Debt

• Debt-to-Equity Ratio: 0.95
• Current Ratio: 4.32
• Quick Ratio: 3.52

Sales & Book Value

• Annual Sales: $87.44 million
• Price / Sales: 0.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 42,948,000
• Free Float: 39,727,000
• Market Cap: $77.31 million
• Optionable: Optionable
• Beta: 0.33